ilumya
(tildrakizumab-asmn)Sun Pharmaceutical Industries, Inc.
Usage: ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy.
5 results
omvoh
(mirikizumab-mrkz)Eli Lilly and CompanyUsage: OMVOH is indicated for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults.selarsdi
(ustekinumab-aekn)Teva Pharmaceuticals USA, Inc.Usage: SELARSDI™ is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in the same age group, and moderately to severely active Crohn’s disease and ulcerative colitis in adults.ustekinumab-ttwe
(ustekinumab-ttwe)Quallent Pharmaceuticals Health LLCUsage: Ustekinumab-ttwe is indicated for the treatment of moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.yesintek
(ustekinumab)Biocon Biologics Inc.Usage: YESINTEK is indicated for treating moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.